European Psychiatry - Volume 41 - April 2017

392 / 916

S388 25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404
women. Thus, AVP may increase the differences between men and
women on social cognition.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0817
Long-term metabolic effect of
second-generation antipsychotics in
first episode of psychosis
J. Vázquez Bourgon ∗ érez-Iglesias
V. Ortiz-García de la Foz respo-Facorro
1 University Hospital Marqués de Valdecilla, IDIVAL, University of
Cantabria, CIBERSAM, Psychiatry, Santander, Spain
2 Institute of Psychiatry, King’s College London, Psychiatry, London,
United Kingdom
3 University Hospital Marques de Valdecilla, IDIVAL, CIBERSAM,
Psychiatry, Santander, Spain
∗ Corresponding author.
Introduction There is growing evidence indicating that the use
of second-generation antipsychotic (SGA) treatments in psychosis
is related to potential metabolic side effects. Previous studies
have shown clear metabolic side effects at short-term (12 weeks).
However, to detect clinically-relevant impairment in metabolic
parameters a long-term follow-up is preferred.
Objectives The aim of this study was to investigate the effect of
aripiprazole, ziprasidone and quetiapine on metabolic measures in
medication-naïve first episode psychosis patients after 1 year of
treatment.
Methods One hundred and sixty-eight, drug-naïve patients, suf-
fering froma non-affective first episode of psychosis, were included
in the present study. Patients were randomly assigned to que-
tiapine, ziprasidone or aripiprazole treatment lines. Weight and
glucemic/lipid parameters were recorded at baseline and after 1
year of treatment. Other clinical and socio-demographic variables
were recorded to eliminate potential confounding effects.
Results Weight (t = −10.85; P < 0.001), BMI (t = −11.38;P < 0.001),
total cholesterol (t = −5.37; P < 0.001), LDL-cholesterol (t =−5.21;
P < 0.001), triglycerides (t =− 5.18; P < 0.001) and the triglyc-
eride/HDL insulin resistance index ( t = −4.09; P < 0.001), showed
statistically significant increments after 1 year of treatment.
Moreover, on comparing the percentage of patients with patho-
logical levels before and 1 year after the antipsychotic treatment,
we detected higher percentages of patients with obesity (5.1% vs.
15.3%; P< 0.001), hypercholesterolemia (23.2% vs. 39.6%; P < 0.001)
and hypertriglyceridemia (5.8% vs. 14.2%; P= 0.021) after 1 year of
treatment.
Conclusions The primary exposure to SGAs during the first year of
psychosis was associatedwith significant increments inweight and
metabolic parameters leading to a significant increment in the pro-
portion of obesity, hypertriglyceridemia and hypercholesterolemia
in our sample.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0818
Lack of differential long-term
metabolic profile of aripiprazole,
quetapine and ziprasidone in first
episode of psychosis
J. Vázquez Bourgon ∗, R. Pérez-Iglesias ,
V. Ortiz-García de la Foz , B. Crespo-Facorro
1 University Hospital Marqués de Valdecilla, IDIVAL, University of
Cantabria, CIBERSAM, Psychiatry, Santander, Spain
2 Institute of Psychiatry King’s College London, Psychiatry, London,
United Kingdom
3 University Hospital Marques de Valdecilla, IDIVAL, CIBERSAM,
Psychiatry, Santander, Spain
∗ Corresponding author.
Introduction The use of second-generation antipsychotic (SGA)
treatments in psychosis has been associated with metabolic
changes. However, there are differences in metabolic profile
between SGAs. In a previous study conducted in our sample of
first episode psychosis patients, we observed that the ziprasi-
done had a more benign metabolic profile compare to aripiprazole
and quetiapine, at short-term (12 weeks). However, to detect
clinically-relevant impairment in metabolic parameters a long-
term follow-up is preferred.
Objectives The aimof this study was to investigate if the differen-
tiated metabolic profile of aripiprazole, ziprasidone and quetiapine
observed at short-term is maintained after 1 year of treatment in a
sample of drug-naïve patients with a first episode of psychosis.
Methods One hundred and sixty-eight, drug-naïve patients, suf-
fering froma non-affective first episode of psychosis, were included
in the present study. Patients were randomly assigned to receive
quetiapine, ziprasidone or aripiprazole. Weight and glucemic/lipid
parameters were recorded at baseline and after 1 year of treatment.
Other clinical and socio-demographic variables were recorded to
eliminate potential confounding effects.
Results No significant differences between antipsychotic groups
(all F < 2.61;P > 0.05) were found in any of themetabolic parameters
studied after one year of treatment.
Conclusions Despite themetabolic profile differences observed at
short-term in our previous studies, we did not find significant dif-
ferences in the metabolic and weight parameters studied between
treatment groups after one year of treatment, concluding that they
present similar metabolic profiles at long-term. Other clinical indi-
vidual interventions (e.g.: diet, exercise), not here controlled, may
have influenced possible differences in long-term metabolic out-
comes.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0819
Differentiated psychopharmacological
treatment in three genetic subtypes of
22q11.2 deletion syndrome
W.M.A. Verhoeven ∗, J.I.M. Egger , N. de Leeuw
1 Vincent van Gogh Institute for Psychiatry, Centre of Excellence for
Neuropsychiatry, Venray, Netherlands
2 Radboud University Medical Centre, Department of Human
Genetics, Nijmegen, Netherlands
∗ Corresponding author.
Introduction The 22q11.2 deletion syndrome (22q11DS), mostly
causedby the commondeletion including the TBX- and COMT-genes
(LCR22A-D), is highly associated with somatic anomalies. The dis-
tal deletion (distal of LCR22D) comprises the MAPK1 -gene and is
associated with specific heart defects. The rare central deletion
(LCR22B-D) encompasses theCRKL -gene and shows predominantly
urogenital anomalies. 22q11DS also differs in its neuropsychiatric
profile: common deletion accompanied by schizophrenia-like psy-
choses and autism spectrum disorders, distal deletion by anxiety
disorders, and central deletion by autistic-like behaviours.
Objectives Investigating genetic subtypes of 22q11DS.
Aims Achieving a targeted pharmacological treatment based on
genetic sub-typing.
Methods Thirty-two patients with genetically proven 22q11DS,
referred for detailed neuropsychiatric analysis.
Results Apart from two patients with distal deletion and one
with central deletion, common 22q11.2 deletion was detected in